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Abstract – The methylation status of the target promoter sequences of p15INK4B ( p15) and O6-methylguanine-DNA 
methyltransferase (MGMT) genes was studied by methylation-specific PCR in 10 adult patients with de novo B-cell non-
Hodgkin lymphoma (B-NHL). The aberrant hypermethylation of the p15 gene was more frequent (50%) compared to 
the hypermethylation of the MGMT gene (30%), and was detected in different types of B-NHL in both genes. Hyper-
methylation of the MGMT gene occurred exclusively in association with the hypermethylation of the p15 gene. All 
lymphoma patients with hypermethylation of the p15 and/or MGMT genes had a higher clinical stage of the disease (IV 
- V). We show the association of anemia and/or thrombocytopenia with the hypermethylation of the p15 gene, ascribing 
the p15 gene as a potential prognostic marker in B-NHL. Comethylation of MGMT with the p15 gene represents a novel 
finding and presents both genes as candidates for future studies of the hypermethylation profiles of B-NHL.  
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INTRODUCTION 
The initiation and development of cancer involves 
several genomic alterations which are generally 
caused by genetic and epigenetic mechanisms (Ha-
nahan & Weinberg, 2000; Verma & Srivastava, 
2002; Baylin & Ohm, 2006). In normal mammalian 
cells, the methylation of cytosine (C) bases within 
the CpG dinucleotide islands of gene promoter 
regions represents the most important epigenetic 
mechanism for the modulation of gene activity 
(Jones et al., 1998; Verma & Srivastava, 2002). DNA 
methylation patterns, called epigenotypes (Esteller, 
2003), are profoundly deranged in different types of 
human cancer (Esteller et al., 2001), including acute 
leukemias and lymphoproliferative disorders 
(Baylin et al., 1998; Rush & Plass, 2002; Esteller, 
2003; Galm et al., 2005). Aberrant hypermethyl-
ation of CpG islands, resulting in the silencing of 
gene expression, has been observed for many can-
cer-related genes (Galm et  al., 2005). Molecular 
pathways affected by DNA methylation changes 
include cell cycle control, cell invasion and adhe-
sion, regulation of apoptosis, DNA damage repair 
and growth-factor response (Galm et al., 2005). 
In normal cells,  the  protein P15, which is a 
product of the gene located at chromosome 9p21 of 
the human genome, acts as a tumor suppressor 
(Herman et al., 1996b) by inhibiting cyclin-dependent 
kinase 4 and 6 activity and inducing cell cycle arrest 
(Sherr & Roberts, 1999). It is also known that P15 is 
one of the intracellular mediators of transforming the 
growth factor β (TGF-β) signaling pathway, a strong 
negative regulator of cell proliferation and promoter 
of hematopoietic stem cells differentiation (Visser & 
Kast, 2002). Hypermethylation of normally 
unmethylated CpG islands of the promoter region of 
the p15
INK4B (p15) gene was detected in some tumor 
cell lines (Paz et al., 2003) and primary human 212  NADA KRAGULJAC KURTOVIĆ ET AL. 
cancers, with highest frequencies in glioma as well as 
in acute leukemia (AL) and non-Hodgkin lymphoma 
(NHL) (Herman et al., 1996b; Drexler, 1998; Baur et 
al., 1999; Galm et al., 2005). 
O
6-Methylguanine-DNA Methyltransferase 
(MGMT) is a unique DNA repair enzyme (E.C. 
2.1.1.63) that removes mutagenic and cytotoxic 
alkyl adducts from the O
6 position of guanine 
(Gerson, 2002; Margison et al., 2003). A deficiency 
of MGMT protein induces the accumulation of 
premutagenic lesions, predominantly O
6-methyl-
guanine, which leads to the fixation of transition G 
→ A and the generation of a “mutator phenotype” 
(Esteller & Herman, 2004). Hypermethylation of 
the promoter region of the MGMT gene, located at 
chromosome 10q26 of the human genome, was 
identified in some tumor cell lines (Paz et al., 2003; 
Bogdanovic et al., 2007) and some of the primary 
human cancers, including NHL (Esteller et al., 
1999; Margison et al., 2003). It has been shown that 
increased methylation of the MGMT gene may be a 
new prognostic marker of survival in patients with 
diffuse large B-cell lymphoma (DLBCL) treated 
with alkylating drugs such as cyclophosphamide 
(Esteller et al., 2002). 
The primary aim of this  pilot study was to 
optimize the methylation-specific PCR (MS-PCR) 
assay for the analysis of p15 and MGMT genes, and 
to evaluate the frequency of aberrant de novo methyl-
ation of these  genes in a selected group of adult 
patients (pts) with different types of de novo B-NHL. 
The second aim of the study was to test the potential 
association of epigenetic changes with the clinico-
pathological characteristics of studied patients.  
MATERIALS AND METHODS 
Patients 
Our study included specimens of 10 adult patients 
with diagnosis (dg) of de novo B-NHL, collected 
between 2001 and 2004. The patients were diagnosed 
and treated at the Institute of Hematology, Clinical 
Center of Serbia. Patients signed informed consent 
prior to specimen collection according to the requi-
rements of the Institutional ethical committee. All 
patients underwent standard diagnostic procedures, 
including cytomorphology with cytochemistry (Hou-
wen, 2000), histopathology (Jack et al., 2005), immu-
nophenotyping by flow cytometry (4/10 pts) (Rothe 
and Schmitz, 1996; Stelzer et al., 1997) or by immu-
nohistochemistry (6/10 pts) (Jack et al., 2005). Patients 
were diagnosed according to the criteria given by the 
World Health Organization (WHO) (Harris, 2001; 
Jaffe et al., 2008), and treated by standard chemo-
therapy protocols for adults with dg B-NHL (Hid-
demann et al., 2005; National Cancer Institute, 2002).  
Peripheral blood and bone marrow specimens 
were anticoagulated by acid-citrate-dextrose (Tatsumi 
et al., 2002). Six out of ten DNA samples were isolated 
from mononuclear cells (MNC) obtained from 
peripheral blood (4 pts) or bone marrow (2 pts). The 
MNC were isolated using a Lympho Separation 
medium (1.077 g/ml, ICN, USA) as reported by 
Boyum (1968). Aliquots of 10 x 10
6 MNC were spun 
down at 720g/5 min, and the pellets were frozen at -
20
oC. In all analyzed specimens, lymphoma cells were 
the predominant population (>90% of total cells). 
Four out of ten DNA samples were isolated from 
tissue sections  (7-8 μm) of formalin-fixed paraffin 
embedded  lymph node blocks, according to the 
protocol by Goelz et al., (1985).  
Control Specimens 
Three specimens of peripheral blood, taken from 
healthy laboratory personnel, as well as three com-
mercial cell lines, were tested in parallel with the 
patients’ specimens. DNA from commercial cell li-
nes. K562 (European Collection of Cell Cultures, 
ECACC No 89121407), established from a patient 
with Chronic Myeloid Leukemia undergoing ery-
throblastic transformation; SuDHL-4 (kindly provi-
ded by Dr. A. L. Epstein, Stanford University, Cali-
fornia, USA), established from a patient with 
Follicular cell NHL, and RAJI (European Collection 
of Cell Cultures, ECACC No. 85011429), established 
from a patient with Burkitt type B-NHL, were used 
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DNA extraction and PCR assay 
Genomic DNA was extracted by standard sodium 
dodecyl sulfate-proteinase K treatment, phenol-
chloroform-isoamylalcohol extraction and ammo-
nium acetate-isopropanol precipitation (Sambrook 
et al., 1989). PCR amplification of unmodified 
genomic DNA (150 ng) using primer sets specific for 
wild-type promoter sequences (W) of p15 and 
MGMT genes (Table 1), was performed according to 
the protocol by Herman et al., (1996a). Wild-type 
sequences of unmodified DNA for both genes cor-
responded to the position of target modified DNA 
sequences selected for methylation status analysis. 
Bisulfite modification of DNA 
Bisulfite modification of 2 μg of genomic DNA was 
performed according to the method originally descri-
b e d  b y  H e r m a n  e t  a l . ,  ( 1 9 9 6 a ) ,  w i t h  s l i g h t  m o d i f i -
cations (Grunau et al., 2001; Krtolica et al., 2007). The 
bisulfite-treated DNA was purified using a QIAquick 
Gel Extraction Kit (Qiagen, Hilden, Germany). 
MS-PCR assay 
An MS-PCR assay was performed to detect the 
methylation status of selected promoter sequences of 
p15 and MGMT genes. Forty μl of bisulfite-modified 
DNA was prepared from each sample and 4 μl was 
amplified using 300 ng of primers specific for the 
methylated (M sets) and unmethylated (U sets) 
sequences (Table 1, Herman et al., 1996a; Esteller et 
al., 1999). DNA amplification was carried out using 
1.25 U Taq DNA polymerase (MBI Fermentas, 
Lithuania) in 50 μl reaction mixture, in a Hybaid 
OmniGene temperature cycler (Hybaid, Teddington, 
UK). Reactions were hot started as an initial 
denaturation step, at 95
oC for 5 min, followed by 33 
cycles of denaturation at 95
oC, annealing at 57
oC and 
extending at 72
oC for 30 s each, with a final 4 min 
extension step at 72
oC.  
All MS-PCR experiments were performed with 
positive and negative controls for both un-
methylated and methylated alleles. Also, control 
experiments without DNA were performed in 
parallel for each set of PCR primers. The products 
were separated by electrophoresis, either on 2% 
agarose gels or nondenaturing 8% polyacrylamide 
gels, stained with SYBR Green I and silver nitrate, 
respectively.  
Statistical analysis 
For statistical purposes, B-NHL patients were 
classified into 2 different methylation groups: 
unmethylated (no methylated genes) and methyl-
ated (at least one methylated gene). For statistical 
analysis of the differences between the groups, 
Fisher’s exact test, Chi-Square test, Student’s T test 
and the Mann-Whitney test were used. Values were 
considered statistically significant if the p value was 
less than 0.05. 
RESULTS  
PCR analysis of unmodified DNA 
PCR amplification of unmodified genomic DNA 
was performed with the aim to identify the presence 
of intact 5’CpG island sequences of the promoter 
region of p15 and MGMT genes. We used wild-type 
DNA from the control samples with W primer sets 
(Table 1) The intact target sequence of the p15 gene 
(137 bp, Fig. 1a) was detected in the control 
peripheral blood (line 1) and cell line SuDHL-4 
(line 3), while it did not amplify in K562 (line 2) 
and RAJI (line 4) cell lines. The intact target 
sequence of the MGMT gene (93 bp Fig. 1b) was 
detected in all examined samples, including the 
control peripheral blood (line 1) and cell lines 
K562, SuDHL-4 and RAJI (lines 2 to 4). 
Optimization of MS-PCR assay 
Optimization of the MS-PCR assay for p15 and 
MGMT genes included two steps. The first was to 
select the optimal annealing temperature for the 
assay. The range of temperatures tested was from 
54
oC to 60
oC and from 54
oC to 59
oC with the U and 
M primer sets, respectively (results not shown). In 
both genes the most abundant specific amplifica-
tion products were obtained at the annealing tem-214  NADA KRAGULJAC KURTOVIĆ ET AL. 
(A) 
(B) 
Fig. 1. Detection of the wild-type sequences of 5' region of p15
(Fig. 1a, 137 bp product) and MGMT (Fig. 1b, 93 bp product)
genes in control specimens. An 8% polyacrylamide gel of PCR
products with W primer set. Line 1, control peripheral blood
from a healthy donor; Line 2, cell line K562; Line 3, cell line
SuDHL-4; Line 4, cell line RAJI; St, Mw Standard (50 bp). 
perature of 57
oC (Table 1). This annealing tempe-
rature was therefore used in further experiments 
with lymphoma samples.  
The second step in optimization was to deter-
mine the optimal concentration of the target DNA 
in the MS-PCR assays. The concentration of mo-
dified DNA was tested in the range from 0.4 μl to 4 
μl of the final DNA volume (40 μl). Results of MS-
PCR amplification with the U and M primer sets of 
the  MGMT gene as a function of DNA concen-
tration are shown in Figure 2a (control peripheral 
blood) and 2b (cell line K562), respectively. The 
most efficient MS-PCR amplification was achieved 
for the highest tested DNA concentration (4 μl) for 
both of the examined genes.  
MS-PCR analysis of B-NHL samples 
The methylation status of the target promoter 
sequences of p15 and MGMT genes was studied by 
MS-PCR in 10 patients with de novo B-NHL (Fig. 3 
and 4) The unmethylated allelic form of the p15 (u-
p15, 154 bp product) and MGMT (u-MGMT, 93 bp 
product) genes was detected in all examined patients 
(10/10, 100%). The presence of the methylated allelic 
form of the p15 gene (m-p15, 148 bp product) was 
shown in half of the tested patients (5/10, 50% pts), 
while in the case of the MGMT gene, a lower 
frequency (3/10, 30%) of methylated allelic form (m-
MGMT, 81 bp product) was detected.  
Three of the five patients with aberrant methyl-
ation of the p15 gene had aberrant methylation of 
the  MGMT gene (m-p15/m-MGMT  profile), 
whereas 2/5 patients had aberrant methylation of 
the p15 gene as a sole aberration (m-p15/u-MGMT 
profile, Table 2). Half of tested patients (5/10, 50%) 
had only unmethylated allelic forms of both genes 
(u-p15/u-MGMT profile, Table 2). 
While expression of m-p15/m-MGMT or m-
p15/u-MGMT profiles did not associate itself with 
 
 
Table 1. Primer sets used for MS-PCR 
Primer set  Sense primer  Antisense primer     Size (bp) / AT  
 p15-WT  5'-CGCACCCTGCGGCCAGA-3'  5'-AGTGGCCGAGCGGCCGG-3'  137bp / 65 
oC 
 p15-M  5'-GCGTTCGTATTTTGCGGTT-3'  5'-CGTACAATAACCGAACGACCGA-3'  148bp / 57 
oC 
 p15-U  5'-TGTGATGTGTTTGTATTTTGTGGTT-3'  5'-CCATACAATAACCAAACAACCAA-3'  154bp / 57 
oC 
MGMT-WT  5'-TTTGCGTCCCGACGCCCG-3’  5’-AGCTCCGCACTCTTCCGG-3’  93bp / 62 
oC 
MGMT-M  5'-TTTCGACGTTCGTAGGTTTTCGC-3’  5’-GCACTCTTCCGAAAACGAAACG-3’  81bp / 57 
oC 
MGMT-U  5'-TTTGTGTTTGATGTTTGTAGGTTTTTGT-3’  5’-AACTCCACACTCTTCCAAAAACAAAAA-3’  93 bp / 57 
oC 
 
Abbreviations: WT, primer set for unmodified wild-type DNA sequence; U, primer set for unmethylated modified DNA sequence;  
M, primer set for methylated modified DNA sequence; AT, annealing temperature.   P15 AND MGMT METHYLATION IN B-NHL  215 
(A) 
(B) 
 
Fig. 2. Testing of the efficiency of MS-PCR amplification of the
sequence of 5’ region of the MGMT gene as a function of the
concentration of modified DNA from: a) control peripheral
blood with U primer set and MS-PCR product of 93 bp; b) cell 
line K562 with M primer set and MS-PCR product of 81 bp.
The lines 1-4 present volume of DNA loaded on 2% agarose
gel: 0.4μl; 1 μl; 2μl; 4 μl; H2O, reaction mix without DNA. 
Fig. 3. Methylation status of p15 gene in patients with dg B-
NHL: 8% polyacrylamide gel of MS-PCR products. U, 154 bp 
product with U primer set ; M, 148 bp product with M primer 
set; pb, control peripheral blood from a healthy donor; St, Mw 
Standard (50 bp); H2O, reaction mix without DNA with M 
primer set. 
any particular type of B-NHL, all patients in 
this group presented a higher clinical stadium 
(CS) of the disease: CS IV or V (Table 2). 
Only 1/5 patients with dg B-NHL-Follicular 
showed hypermethylation of the studied 
genes, having an m-p15/m-MGMT profile 
(Table 2, pt NHL-8).  
p15 and MGMT gene methylation status and 
clinicopathological features 
We examined the relationship between the p15 
or  MGMT gene methylation status and the 
clinicopathological features of the patients 
(Table 3). In the group with the m-p15 allelic 
form of the gene, we found that there is a 
statistically significant lower median hemo-
globin value compared to the group with u-p15 
allelic form (p=0.004, t-test). The same trend of 
decreased hemoglobin values, although sta-
tistically insignificant, was shown for the group 
of patients with an m-MGMT allelic form of the 
MGMT gene. In the group of patients with an m-
p15 a l l e l i c  f o r m  o f  t h e  g e n e  w e  a l s o  f o u n d  a  
lower, although statistically insignificant, 
median platelet level. Further analysis revealed a 
significant association between the presence of 
an m-p15 allelic form of the gene and decreased 
platelet levels (<150.000 x 10
9/l, p=0.038, Mann-
Whitney test). The methylation status of the 
MGMT gene was independent of platelet values.  
Patients with an m-MGMT allelic form of the 
MGMT gene showed a trend towards a lower me-
dian leucocyte value, as well as lower proportions of 
lymphoma cells in the peripheral blood and bone 
marrow, compared to the group of patients with a 
u-MGMT allelic form of  the gene (Table 3). The 
methylation status of the p15 gene was independent 
of the leucocyte values.  
There was no correlation between the methy-
lation status of the p15 and MGMT genes and the 
gender and age of the patients. Analysis of the res-
ponse to the therapy did not reveal clear differences 
between the groups with different gene methylation 
profiles (data not shown). 
DISCUSSION 
The profile of CpG island hypermethylation in 
hematological malignancies is an epigenetic signa-
ture unique for each subtype of acute leukemia or 
lymphoma (Esteller, 2003). NHL exhibits non-ran-
dom methylation patterns in which germinal center 
tumors seem to be prone to de novo methylation 216  NADA KRAGULJAC KURTOVIĆ ET AL. 
 
 
Table 3. Clinical and hematological characteristics of B-NHL patients in correlation to the methylation status of p15 and MGMT genes
P Pa ar ra am me et te er r    m m- -p p1 15 5   g ge en ne e    u u- -p p1 15 5   g ge en ne e    p p   v va al lu ue e    m m- -M MG GM MT T   g ge en ne e    u u- -M MG GM MT T   g ge en ne e    p p   v va al lu ue e   
S Se ex x   ( (% %) )   
male   
female   
3/5 (60) 
2/5 (40) 
4/5 (80) 
1/5 (20) 
0.490 
2/3 (67) 
1/3 (33) 
5/7 (71) 
2/7 (29) 
0.880 
A Ag ge e   ( (y ye ea ar r) )   
(x±SD)   
53 ± 13  55 ± 18  0.850  57 ± 17  52 ± 16  0.691 
L Le e   ( (x x1 10 09 9/ /l l) )   
(x±SD)   
29 ± 44  23 ± 25  0.810  5 ± 3  35 ± 37  0.219 
P Pl lt t   ( (x x1 10 09 9/ /l l) )   
(x±SD)   
135 ± 84  214 ± 71  0.147  183 ± 69  171 ± 95  0.849 
P Pl lt t   ( (% %) )   
(>150 x10
9/l)   
(<150 x10
9/l)   
2/5 (40) 
3/5 (60) 
5/5 (100) 
0/5 (0) 
0.038* 
2/3 (67) 
1/3 (33) 
5/7 (71) 
2/7 (29) 
0.880 
H Hb b   ( (g g/ /d dl l) )   
(x±SD)   
92 ± 21  134 ± 9  0.004*  98 ± 21  119 ± 28  0.278 
P PB B   L Ly yC C   ( (% %) )   
(x±SD)   
59 ± 29  51 ± 31  0.676  41 ± 19  61 ± 31  0.337 
B BM M   L Ly yC C   ( (% %) )   
(x±SD)   
57 ± 31  67 ± 19  0.709  50 ± 39  65 ± 24  0.598 
 
Abbreviations: u, unnmethylated; m, methylated; PB LyC, peripheral blood lymphoma cells; BM LyC, bone marrow lymphoma cells; 
Le, leukocytes; Plt, platelet; Hb, hemoglobin; *, statistically significant (p<0.05). 
Table 2. Basic clinical and biological characteristics of patients with dg B-NHL
Patient   Sex / Age   Sample type  Immuno-hisopathologic type / CS 
p15 / MGMT gene 
methylation status 
NHL-1  F / 34  PB  B-NHL-Follicular / VB  u / u 
NHL-2   M / 65  PB  B-HLL/SLL / II  u / u 
NHL-3  F / 41  PB  B-NHL-Marginal zone / IV  m / u 
NHL-4  M / 66  BM  B-NHL, NOS, low grade / IVB  m / m 
NHL-5  M / 38  BM  B-NHL-Lymphoplasmocytic, IgGkappa / IVB  m / m 
NHL-6  M / 52  PB  B-NHL-Mantle zone / V  m / u 
NHL-7  M / 50  LN  B-NHL-Follicular / IIEA  u / u 
NHL-8  F / 67  LN  B-NHL-Follicular / IVA  m / m 
NHL-9  M / 81  LN  B-NHL-Follicular / IIIB  u / u 
NHL-10  M / 44  LN  B-NHL-Follicular / IVB  u / u 
 
Abbreviations: M, male; F, female; PB, peripheral blood; BM, bone marrow; LN, lymph node; CS, clinical stage; NOS, 
not otherwise specified; u, unmethylated; m, methylated.   P15 AND MGMT METHYLATION IN B-NHL  217 
 
Fig. 4. Methylation status of the MGMT gene in patients with 
dg B-NHL: 8% polyacrylamide gel of MS-PCR products. U, 93 
bp product with U primer set; M, 81 bp product with M primer 
set; pb, control peripheral blood from a healthy donor; St, Mw 
Standard (50 bp); RAJI, positive control for methylated allelic 
form of MGMT gene. 
(Shi et al., 2007). Although the list of hypermethy-
lation-repressed genes in these neoplasms is expan-
ding very rapidly, particular methylotypes for 
specific NHL subtypes have been examined in only 
a few studies (Rossi et al., 2004; Shi et al., 2007). 
We examined the frequency of aberrant de novo 
hypermethylation of 5’CpG islands located in the 
promoter region of p15 and MGMT genes by per-
forming MS-PCR analysis of the bisulfite-modified 
genomic DNA in selected group of adult patients 
with different types of primary B-NHL. According 
to literature data, both genes p15 and MGMT are 
unmethylated in normal “healthy” hematopoietic 
cells (Herman et al., 1997; Cameron et al., 1999; 
Margison et al., 2003) and are indicated as potential 
methylation markers for B-NHL (Esteller, 2003). 
In this study we applied the MS-PCR assay, the 
most widely-used technique for qualitative methy-
lation analysis of CpG islands of different genes in-
volved in human cancer (Esteller et al., 2002; Galm 
et al., 2006). This approach applies to genes with 
known gene sequences. The high sensitivity of this 
technique, with a detection limit of approximately 
0.1% of methylated DNA present in an otherwise 
unmethylated sample, allows qualitative DNA me-
thylation analysis not only of fresh or frozen tissues, 
peripheral blood, bone marrow and body fluids, but 
also of paraffin-embedded samples (Herman et al., 
1996a; Galm et al., 2006; Krtolica et al., 2007).  
Although, the methodology of bisulfite modifi-
cation of DNA as well as the MS-PCR assay have 
been well standardized (Herman et al., 1996a; 
Grunau et al., 2001), prior to initiation of the analy-
sis we optimized two parameters - the annealing 
temperature for U and M primer sets and the con-
centration of modified target DNA. In the case of 
both genes p15 and MGMT, we found that the most 
efficient specific amplification products for both 
primer sets U and M, were obtained using an 
annealing temperature of 57
oC. This temperature 
was lower than that originally proposed for iden-
tical primer sets, 60
oC for p15 gene (Herman et al., 
1996a) and 59
oC for MGMT gene (Esteller et al., 
1999). In accordance with published data, the opti-
mal chosen concentration of modified DNA (4μl) 
gave the most efficient amplification product for 
both studied genes (Herman et al., 1996a; Grunau 
et al., 2001). 
As a control experiment for MS-PCR, we 
performed PCR amplification of unmodified DNA 
(Herman et al., 1996a), with the aim to validate the 
presence of wild-type promoter sequences of p15 
and  MGMT genes in native unmodified DNA 
samples. The aim of this test was to ensure the 
DNA integrity of potential cases in which an MS-
PCR assay would fail to give any product of 
amplification. In all of the tested patients’ samples 
we found intact promoter sequences of both genes. 
The intact target sequence of the p15 gene was not 
validated for the cell lines K562 and RAJI. Absence 
of p15 promoter amplification was anticipated for 
K562, since it contains 9p21 deletion that comprises 
a locus of the p15 gene (Hatta et al., 1995; Drexler, 
1998). However, our finding that RAJI also lacks 
this region was unexpected since the published data 
(Herman et al., 1996a; Drexler, 1998) indicated that 
the wild-type sequence of the p15 gene was intact. A 
possible explanation for this is that the continuous 
passaging of the RAJI cell line might have induced 
an unknown mutation within the 5’CpG islands of 
p15 gene promoter.  
Since the MS-PCR assay was performed on 
unsorted samples of lymphoma cells which are 
heterogeneous and invariably contaminated with 218  NADA KRAGULJAC KURTOVIĆ ET AL. 
normal cells, we could not identify the type of 
aberrant methylation, biallelic vs. monoallelic, of 
the studied genes (Esteller et al., 1999). On the 
other hand, we revealed the biallelic type of 
aberrant methylation of the MGMT gene in all of 
the tested cell lines, K562, SuDHL-4 and RAJI. This 
finding is in agreement with the published profile of 
MGMT gene methylation in other human cancer 
cell lines (Esteller et al., 1999; Paz et al., 2003). 
Inactivation of the p15 gene by promoter 
hypermethylation is one of the most studied 
epigenetic changes in hematological malignancies, 
especially in acute leukemias and myelodysplastic 
syndromes (Rush & Plass, 2002; Esteller, 2003; 
Galm et al., 2006). According to the published data, 
p15 hypermethylation is extremely common in 
leukemias and relatively rare in lymphomas (Es-
teller, 2003; Galm et al., 2006). Moreover, inacti-
vation of the p15 gene by genetic mechanisms, 
either by point mutations (Baur et al., 1999) or by 
homozygous deletion of chromosome 9p21 (Her-
man et al., 1997), is very rare. Our preliminary data 
showed that the frequency of hypermethylation of 
the p15 gene was 50% (5/10 pts) in the whole B-
NHL group. Our data are in agreement with  the 
results of study by Baur et al., (1999), who reported 
a frequency of 55% for aberrant p15 methylation in 
an unselected group of low risk B-NHL.  
With respect to the type of examined B-NHL, 
we detected p15 hypermethylation in all the studied 
B-NHL types, except B-HLL/SLL. Despite the small 
number of cases in our study, our results were in 
accordance with the data reported by other groups 
(Baur et al., 1999; Martinez-Delgado et al., 2000).  
Published data indicate that hypermethylation 
of the p15 gene plays an important role in the 
different steps of lymphomagenesis, including the 
phase of disseminated disease, which is in positive 
correlation with a higher CS of the disease (Baur et 
al., 1999; Martinez-Delgado et al., 2000). All lym-
phoma patients with an m-p15 allelic form had 
higher CS of the disease (IV - V). Hypermethyla-
tion of the p15 gene could be generated as a pri-
mary de novo (Martinez-Delgado et al., 2000) or as 
a secondary de novo aberration caused by chemo-
therapeutic treatment (Au et al., 2003). The silen-
cing of the p15 gene by hypermethylation can lead 
to the loss of sensitivity of the lymphoma cells to 
growth inhibition by TGF-β and interferon-α, the 
potent regulators of differentiation and prolifera-
tion of lymphohematopoietic cells (Herman et al., 
1997; Sherr & Roberts, 1999; Sangfelt et al., 1999; 
Visser & Kast, 2002).  
A statistically significant positive association of 
different clinicopathological features (especially 
anemia and thrombocytopenia) with the presence 
of hypermethylation of the p15 gene, represents a 
novel finding. Anemia and thrombocytopenia are 
associated with disseminated disease and bone 
marrow infiltration that reflect a higher CS of the 
disease (Jaffe et al., 2008). 
MGMT is one of the genes that is frequently 
hypermethylated in the major types of B-NHL 
(Esteller et al., 1999; Esteller et al., 2002; Rush & 
Plass, 2002). Our preliminary data showed that the 
frequency of overall hypermethylation of MGMT 
gene was 30% (3/10 pts) in our B-NHL group at 
diagnosis. The frequency of hypermethylation of 
the MGMT gene is reported in the literature to be 
between 25% for an unselected group of B-NHL 
(Esteller et al., 1999; Rossi et al., 2004) and 36% for 
a selected DLBCL type (Esteller et al., 2002), and 
these results that are in agreement with our data. 
All three patients with a hypermethylated allelic 
form of the MGMT g e n e  h a d  a  h i g h  C S  o f  t h e  
disease (IV) and were comethylated for the p15 
gene. There are few literature reports that explain 
the potential role of hypermethylation of the 
MGMT gene in lymphomagenesis. They suggest 
that loss of the MGMT protein from the cells in the 
early phase of the disease can cause the generation 
of a new mutator phenotype characterized by G → 
A transitions and the generation and accumulation 
of point mutations in various genes involved in 
cancer etiology, such as the tumor suppressor p53 
and the oncogene K-ras (Esteller et al., 1999; 
Esteller & Herman, 2004). From this point, it is 
important to note that MGMT  hypermethylation   P15 AND MGMT METHYLATION IN B-NHL  219 
alone is a poor prognostic factor in many human 
cancers (Esteller & Herman, 2004). On the other 
hand, loss of the MGMT protein from tumor cells 
due to aberrant hypermethylation can predict a 
better chemoresponse of human tumors to alky-
lating agents such as cyclophosphamide and others 
(Esteller & Herman, 2004).   
Clinicopathological parameters showed a po-
sitive but insignificant association with the presence 
of hypermethylation of the MGMT gene, presenting 
a lower median value of hemoglobin and leuko-
cytes, as well as a lower median proportion of peri-
pheral blood and bone marrow lymphoma cells.  
The comethylation of the MGMT with the p15 
gene, as we report in our study, represents a novel 
finding and selects both genes as candidates in 
future studies of the hypermethylation profiles of B-
NHL. The biological and clinical significance of this 
association remains undetermined due to the small 
size of the patient group involved in this study. 
Similar comethylation of the p16 with the p15 gene 
has been previously reported (Baur et al., 1999; 
Martinez-Delgado et al., 2000). 
In summary, aberrant DNA hypermethylation 
of the p15 and MGMT genes in B-NHL could play a 
role as an epigenetic biomarker with possible 
applications in diagnostics and the monitoring of 
treatment efficacy (Rush & Plass, 2002; Esteller, 
2003; Galm et al., 2006; Shi et al., 2007).   
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УЧЕСТАЛОСТ АБЕРАНТНЕ METИЛАЦИЈЕ ПРОМОТОРА ГЕНА P15
INK4B И O
6-МЕТИЛГУАНИН-
ДНK МЕТИЛТРАНСФЕРАЗЕ KOД Б-ЋЕЛИЈСКОГ НЕХОЏКИНОВОГ ЛИМФОМА:  
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Метилациони статус таргет промоторских 
секвенци гена p15 и O
6-метилгуанин-ДНK 
метилтрансферазе (MGMT) je у нашој пилот 
студији истраживан применом методе мети-
лација зависним PCR-oм (MS-PCR) koд 10 па-
цијената сa дијагнозом de novo Б-нехочкинског 
лимфома (B-NHL). Аберантна хиперметилација 
p15 гена je учесталија (50%) у oдносу нa аберан-
тну хиперметилацију MGMT гена (30%), и утвр-
ђена је код различитих типова B-NHL у случају 
оба испитивана гена. Хиперметилација MGMТ 
гена je oткривена искључиво у асоцијацији са 
хиперметилацијом  p15 гена. Сви пацијенти сa 
хиперметилацијом p15 и/или MGMT  гена имали 
су виши клинички стадијум болести (IV – V). 
Значајна асоцијација анемије и/или тромбоци-
топеније са хиперметилацијом p15 гена, указује 
на његов потенцијални прогностички значај у B-
NHL. Кометилација MGMT и p15 гена пред-
стављa нов податак, и издваја ове гене као кан-
дидате у будућим истраживањима хиперметила-
ционих профила у B-NHL. 
 
 
 
 